Company Overview and News

 
QVC Inc. - This 6.375% Baby Bond Has Begun Trading On The NYSE With A Lot Of Selling Pressure

2018-09-20 seekingalpha
Comparison with all other baby bonds that pay a fixed rate and have a maturity of between 40 and 60 years.
PRU QRTEA PFK GNCMB QVCB GLIBA QVCA QVCD GNCMA LVNTB PRH LVNTA PJH

54
Is Goldman Sachs Mulling the Spin-Off of Fintech App Simon?

2018-09-20 zacks
Goldman Sachs (GS - Free Report) might spin-off Simon — its online platform for retail bond investors — to benefit from the company’s internal technology, while retaining a minority stake. The app, which was rolled out three years back, is currently valued at about $100 million, per The Wall Street Journal. The platform has greatly helped retail brokers who invest on behalf of their clients. It helps them know about the structured investments online, saving time that would otherwise been wasted by discussing about the products over telephone.
HSB UGLD MS PRU BAC DSLV CSSLF PFK HCS PRH PJH WFCNP DGLD LB CS BAC UBS HSBC HBCYF WFC VIIX VIIZ 0005 CSGKF HSEA HSEB ZIV USLV TVIX ULSGF XIV

5
Goldman Sachs nears deal to sell its fintech app: source

2018-09-19 channelnewsasia
REUTERS: Goldman Sachs is in advanced talks with several financial companies to spin off its three-year-old app, Simon, which sells complex financial products to retail investors, a source familiar with the matter told Reuters.
WFCNP BCS HSB 83SF 83SK HSBC HBCYF 47MC WFC PRU PFK HCS 0005 PRH HSEA HSEB PJH

5
Goldman Sachs nears deal to sell its fintech app: source

2018-09-19 reuters
(Reuters) - Goldman Sachs (GS.N) is in advanced talks with several financial companies to spin off its three-year-old app, Simon, which sells complex financial products to retail investors, a source familiar with the matter told Reuters.
WFCNP BCS HSB 83SF 83SK HSBC HBCYF 47MC WFC PRU PFK HCS 0005 PRH HSEA HSEB PJH

4
Goldman shares rise as rivals line up to take stakes in bank's 'Simon' investing app

2018-09-19 cnbc
Goldman Sachs shares jumped 2 percent after word it has lined up rival banks to take stakes in its three-year-old app devoted to selling complex investment products.
WFCNP HSB MS HSBC HBCYF WFC PRU PFK HCS 0005 PRH HSEA HSEB PJH

4
Goldman Sachs nears deal to sell its fintech app: WSJ

2018-09-19 channelnewsasia
Goldman Sachs is in advanced talks with several financial companies to spin off 'Simon', its three-year-old app that sells financial products to retail investors, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
WFCNP HSB HSBC HBCYF WFC PRU PFK HCS 0005 PRH HSEA HSEB PJH

4
Goldman Sachs nears deal to sell its fintech app: WSJ

2018-09-19 reuters
(Reuters) - Goldman Sachs (GS.N) is in advanced talks with several financial companies to spin off ‘Simon’, its three-year-old app that sells financial products to retail investors, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
WFCNP HSB HSBC HBCYF WFC PRU PFK HCS 0005 PRH HSEA HSEB PJH

 
The Fed has some big decisions to make starting next week

2018-09-19 cnbc
When the Federal Reserve gathers next week, markets likely will be looking past a widely expected rate hike and toward the direction the central bank will chart ahead.
PRU PRH PFK MS PJH

 
ASX set to open flat as trade angst returns

2018-09-16 theage.com.au
Australian stocks are poised to open flat, though gains could be checked by renewed US/China trade worries. ASX futures were at 6174 points early on Monday morning after Wall Street's benchmarks edged higher into the close.
PALAY PRU WOPEF PDN PFK TWODF WPL OGFGY BCHEY WOPEY PDN BEPTF BPT PALAF NDAQ PRH OGFGF TWODY PJH TW ORG

 
ASX set to open flat as trade angst returns

2018-09-16 smh.com.au
Australian stocks are poised to open flat, though gains could be checked by renewed US/China trade worries. ASX futures were at 6174 points early on Monday morning after Wall Street's benchmarks edged higher into the close.
PALAY PRU WOPEF PDN PFK TWODF WPL OGFGY BCHEY WOPEY PDN BEPTF BPT PALAF NDAQ PRH OGFGF TWODY PJH TW ORG

21
US stocks end flat amid worries over Fed, trade

2018-09-14 channelnewsasia
NEW YORK: Wall Street stocks finished essentially flat on Friday (Sep 14), with worries about higher interest rates and the US-China trade fight weighing on sentiment.
PRU PRH PFK AMD PJH

 
Saturn Oil & Gas Announces USD $20 Million Senior Secured Note Facility with Prudential Capital Group

2018-09-14 globenewswire
SASKATOON, Saskatchewan, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Saturn Oil & Gas Inc. (“Saturn” or the “Company”) (TSX.V: SOIL) (FSE: SMK) is pleased to announce that it has entered into a USD $20 million senior secured revolving note facility (the "Notes") with Prudential Capital Energy Partners, the middle-market energy mezzanine fund business sponsored by Prudential Capital Group. Under the terms of the Notes, Saturn has elected and qualified for an initial issuance of Notes equal to approximately USD $4.
PRU PRH PFK PJH

39
Oneok Is A Good Fixed Income Play - Cramer's Lightning Round (9/12/18)

2018-09-13 seekingalpha - 1
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, September 12.
PRU HD PFK TRXC ISRG PRU HOME IQ PRH ROKU OKE PJH

9
Stocks making the biggest move premarket: AAPL, NIO, GILD, TEVA, BMY & more

2018-09-12 cnbc
Apple – Apple is expected to introduce new iPhones at an event to be held at the Apple campus in Cupertino, California at 1:00 p.m. ET.
WFCNP NLSN WCG XL DTK WFC PRU GILD PFK PRH XLGLF PJH

 
Prudential CEO to retire after 10 years in the role

2018-09-12 marketwatch
Prudential Financial Inc. PRU, -1.05% said Wednesday Chief Executive John Strangfeld will retire, effective Nov. 30, after about 10 years in the role. The insurer said Charles Lowrey, who has been chief operating officer since April 2014, will be the next CEO. Strangfeld will remain non-executive chairman until April 5, 2019, after which Lowrey will assume the role of chairman. Separately, the company said named Chief Financial Officer Robert Falzon as vice chairman, to succeed current Vice Chairman Mark Grier in December 2018.
PRU PRH PFK PJH

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 744320607